Article: MedImmune In-Licenses Novel Inflammatory Disease Target and The Year in Review, Celgene Corp.

M2 PRESSWIRE-29 December 2006-U.S. Equity News: MedImmune In-Licenses Novel Inflammatory Disease Target and The Year in Review, Celgene Corp.(C)1994-2006 M2 COMMUNICATIONS LTD

RDATE:29122006

City of Industry, CA - Biotechnology industry alert provided by U.S. Equity News. MedImmune, Inc. (Nasdaq: MEDI) recently announced that it intends to develop a monoclonal antibody (MAb) targeting pathways within the CD28 receptor family for treatment of certain inflammatory diseases under a recently signed license agreement with Japan Tobacco, Inc. (JT). MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!